Nominate first liver development candidate

Delivered after the deadline

AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.

Announced: 12 Jan 2021
Due: 31 Dec 2021
Delivered: November 2022

Deadline
Met
Late
Not met
Today

What the company said

“Nominate first liver development candidate”

SourceBeam Therapeutics Inc. Form 8-K press release, 2021-01-12
FilingSEC filing index
Deadline as statedin 2021
Deadline used31 Dec 2021, the last day of the stated period
TypeProduct
Permanent referenceKI-C-2021-BEAM-021938
Cite as https://keptindex.org/c/KI-C-2021-BEAM-021938/ — this address never changes.

What we found

Evidence strength A What the grades mean

The company announced BEAM-302 as a development candidate in November 2022, fulfilling the commitment to nominate a second liver development candidate within the 2022 calendar year.

A
Beam Therapeutics Inc. 10-K filed 2023-02-28 Regulatory filing · published 28 Feb 2023 · retrieved 2 Oct 2026 · kept permanently by the SEC · fingerprint 7d449214f52a
“In November 2022, we announced BEAM-302 as a development candidate” ✓ confirmed on the page

Checked 2 Oct 2026.

Commitment lineage

Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.

Deadline drift +365 days
2 versions

Version 1 · original · stated 12 Jan 2021

Deadline 31 Dec 2021 (“in 2021”)
Version 2 · stated 10 Jan 2022

Deadline 31 Dec 2022 (“2022”) · target 2 candidate

“Nominate 2nd liver development candidate”
Source for this version

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type: Product other
Indicative materiality: Low rules
Action: Nominate
Deliverable: First liver development candidate
In the company’s control: High
Specificity: High

How this entry was checked

Commitment recordedThe company's words were matched word for word against the filing.
First checkAn AI model read the company's later filings and recorded the outcome with a quoted passage.
Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.

Confirmed. This outcome counts towards the company's Kept Score. How verification works

Are you Beam Therapeutics Inc.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.